1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Brookfield announced a non-binding framework agreement between the U.S. Government and South Korea to support up to $120 billion of Korean investment in eight large nuclear reactors in the U.S. Brookfield is a shareholder in Westinghouse alongside Cameco, and the framework includes a planned Korean equity investment of 5% to 10% in Westinghouse, but the filing does not quantify Brookfield's own financial effect.
Up to $120 billion of Korean investment to help finance eight large U.S. reactors
Six Westinghouse AP1000 reactors across three two-unit plants, plus two APR1400 reactors, on U.S. federal sites
Korea would make a cornerstone equity investment of between 5% and 10% in Westinghouse
Terms are non-binding and subject to final negotiations
Sanara MedTech shareholders approved the merger agreement with MiMedx Group at a special meeting on September 30, 2026, with 6,372,989 votes for and 1,944 against. Shareholders also approved, on an advisory basis, merger-related compensation for Sanara's named executive officers. The merger still depends on the expiration of the HSR Act waiting period and the satisfaction or waiver of other closing conditions.
OpenText said it will buy up to $300,000,000 of its 3.875% Senior Notes due 2028 in a cash tender offer, but holders tendered $697,563,000, so purchases are prorated at 43.047752%. The company expects a concurrent senior secured notes offering to close on October 1, 2026, with proceeds and cash on hand used to redeem its 6.900% Senior Secured Notes due 2027 and to pay for the tendered 2028 notes. The filing concerns debt refinancing and does not report earnings or guidance.
Accepts up to $300,000,000 aggregate principal; $697,563,000 principal tendered; proration factor 43.047752%.
Tender Offer Consideration of $981.71 per $1,000 principal, set at a fixed spread of +50 basis points over the 4.250% U.S. Treasury due February 15, 2028 (reference yield 4.773%).
Tender expired 5:00 p.m. New York City time on September 30, 2026; settlement expected October 2, 2026.
Concurrent senior secured notes offering expected to close October 1, 2026, to fund the redemption of the 6.900% Senior Secured Notes due 2027.
Sagimet Biosciences agreed on September 30, 2026 to sell 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants for up to 2,750,010 shares, with net proceeds expected to be $107.5 million. The company plans to use the proceeds with its existing cash to fund a Phase 3 trial of denifanstat in acne, pre-launch activities, and other clinical and corporate needs, and the offering is expected to close on October 1, 2026.
8,750,010 common shares offered at $10.00 per share, plus pre-funded warrants for up to 2,750,010 shares
Expected net proceeds of $107.5 million after underwriting discounts and commissions
Offering expected to close October 1, 2026, subject to customary closing conditions
Underwriters include Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives
SunCoke Energy said senior vice president P. Michael Hardesty will retire after 15 years with the company and will continue to advise on commercial operations and business development. Ryan D. Osterholm, who joined the company in October 2007, was promoted to succeed him as senior vice president, commercial operations and business development, as part of a leadership succession program. The change is a planned management transition, and the filing gives no financial results.
Hardesty, age 63, is retiring as senior vice president, commercial operations, business development, international coke and terminals, and will advise the company after retiring.
Osterholm, age 51, has been vice president, commercial operations and business development since August 2025.
Osterholm will receive a $440,000 annual base salary and a non-equity incentive target equal to 60% of base salary.
Neptune Insurance Holdings' board increased its size from six to seven directors and elected David Noble to fill the new seat, effective immediately, as a Class I director with a term through the 2029 annual meeting. The board determined Noble is independent, and he will receive restricted stock units covering 28,704 Class A shares that vest over three years, starting September 30, 2027.
David Noble elected to board on September 30, 2026; board expanded from six to seven directors
Board has determined Noble is independent under SEC and NYSE rules; committee assignments not yet determined
RSU award covers 28,704 Class A common shares; one third vests September 30, 2027, remainder quarterly thereafter
Company issued press release on September 30, 2026 announcing the appointment, furnished as Exhibit 99.1
Standard BioTools ended its agreement to sell its mass cytometry business to Multiplex Bio and agreed to sell it to Element Biosystems, a subsidiary of GMT Venture, for $5.5 million in cash. The company agreed to pay Multiplex Bio a $1.5 million termination fee, of which GMT Venture will pay $1.0 million, and says the Element deal increases its net cash position by about $15 million compared with the Multiplex Bio transaction, which the Treeline merger exchange ratio takes into account. Completion still depends on stockholder approval and the pending Treeline merger.
Multiplex Bio purchase agreement terminated on September 30, 2026; the company agreed to pay a $1.5 million termination fee, with GMT Venture paying $1.0 million of it on the company's behalf.
Element purchase price is $5.5 million in cash, on a cash-free and debt-free basis, with no financing condition and a GMT Venture equity commitment letter.
Closing requires stockholder approval and consummation of the Treeline merger; the company expects the Element deal to close by the end of 2026.
If the deal terminates in specified circumstances, the company owes Element a $1.0 million termination fee; expense reimbursements of up to $125,000 each apply if closing misses December 31, 2026 or March 31, 2027.
Streamex Corp. said interim executive chairman Morgan Lekstrom resigned from that role effective September 30, 2026, and will remain an independent board member. The company has not yet named a successor as executive chairperson, so shareholders will not know who will lead the board in that role until one is identified. The filing contains no financial results, despite the Item 2.02 heading.
Lekstrom resigned as interim executive chairman on September 24, 2026, effective September 30, 2026.
He will keep his position as an independent member of the Board of Directors.
No successor as executive chairperson has been identified yet.
The filing includes no revenue, profit, or guidance figures.
On September 30, 2026, Solana Company agreed to sell 4,369,356 Class A shares at $3.433 each to a single institutional investor, with warrants for the same number of shares at $3.776. Gross proceeds are expected to be about $15 million, or about $14.3 million net, and the offering is expected to close on or about October 1, 2026. The issuance adds new shares that existing shareholders will share in, and the company plans to use the proceeds to accumulate SOL, buy back stock, and for working capital and other purposes.
4,369,356 Class A shares sold at $3.433 per share, with warrants for up to 4,369,356 shares at $3.776 per share
Gross proceeds about $15 million; net proceeds about $14.3 million; placement agent cash fee of 4.0% of gross proceeds
Shares priced at a 5% premium to net asset value per share; company reported total NAV of $278 million as of September 24, 2026, with SOL at $119
Closing expected on or about October 1, 2026; Clear Street served as exclusive placement agent
MacKenzie Realty Capital reported fiscal 2026 results for the year ended June 30, 2026, with net revenues down 9% and net loss down 41%. The same day, its Board temporarily suspended the Preferred Share Repurchase Program so it can react to strategic alternatives that its financial advisor, Maxim Group LLC, may bring. The Board says the company's issuance of common stock in exchange for preferred shares added selling pressure on the common stock, and it expects to reassess the program in due course.
Net revenues were $20.01 million for fiscal 2026, down 9% from $22.06 million in fiscal 2025.
Net loss was $14.13 million, down 41% from $23.97 million; net operating loss was $15.61 million, down 33% from $23.46 million.
The Preferred Share Repurchase Program is temporarily suspended; the Board expects to reassess it in due course.
The company says there can be no assurance that it will enter into any strategic transaction.
Cheetah Net Supply Chain Service Inc. disclosed progress on its at-the-market share sale program with Pacific Century Securities, which allows sales of Class A common stock of up to $35.3 million. As of September 25, 2026, the company had sold about 196,850,000 shares under the program, before the reverse split took effect on September 28, 2026. After the 1-for-150 reverse split, the company reports about 1,332,087 Class A and 1,358 Class B shares outstanding, a much smaller share count for existing holders.
ATM Offering authorizes sales of Class A common stock with an aggregate offering price of up to $35.3 million, under an agreement entered August 21, 2026
About 196,850,000 shares sold under the ATM Offering as of September 25, 2026, before giving effect to the reverse split
1-for-150 reverse split of Class A and Class B common stock became market effective September 28, 2026
After the split, about 1,332,087 Class A and 1,358 Class B shares are issued and outstanding
On September 24, 2026, a Zone Frontier subsidiary entered a Ground Lease covering about 4,077 acres in Potter County, Texas, for the West Texas data center campus it is developing with HST Technologies. Base rent starts only when construction begins on each site area, and the company can terminate the lease before its inspection period ends, with a refund of its $250,000 deposit subject to a partial non-refundable portion. The lease's commencement depends on conditions such as utility commitments for at least 200 MW of firm service, so the project's path to revenue remains uncertain.
Ground Lease dated September 24, 2026 covers about 4,077 acres; 200 to 800 acres may be designated for data center use and at least 1,800 acres for solar and battery storage
Initial term of 30 years with two 10-year extension options
Base rent is $6,000 per acre per year for the data center area and $1,000 per acre per year for the solar area, beginning only when construction starts on each area
Purchase option for the data center site at $100,000 per acre before on-site power commercial operation, or $135,000 per acre on or after that date; $250,000 deposit is credited against the price if exercised
Newbury Street II disclosed a $350,000 advisory engagement with Donerail Group, an affiliate of former director William Zachre Wyatt, who resigned from the board on September 29, 2026 to avoid a conflict of interest. The company also said it and Fort Robotics confidentially submitted a draft Form S-4 for the proposed business combination, which is expected to close in the fourth quarter of 2026 or the first quarter of 2027, subject to approvals and a shareholder vote.
Donerail engagement letter dated September 29, 2026: $350,000 cash fee plus expense reimbursement up to $75,000, payable at closing.
Sponsor to grant Donerail interests corresponding to about 599,166 Class B ordinary shares upon closing, with an equal amount forfeited by Thomas Bushey.
William Zachre Wyatt resigned as a director effective September 29, 2026; Anthony James Vinciquerra is entitled to 50% of Donerail's net economic interests.
Draft Form S-4 submitted September 29, 2026; the transaction values Fort Robotics at an enterprise value of about $556.6 million and is expected to provide about $201 million in gross proceeds.
Five Point Holdings extended its Development Management Agreement with Heritage Fields El Toro, LLC, owner of the Great Park Neighborhoods community, through December 31, 2028, after the prior term was set to end December 31, 2026. The base fee is unchanged at $13.5 million a year, while incentive compensation drops to 6.75% of future distributions if the agreement is not extended beyond 2028.
Amendment dated September 25, 2026 extends the DMA term to December 31, 2028 (Third Renewal Term)
Annual base fee remains $13.5 million, paid monthly, unchanged from current level
Incentive Compensation is 9% of Great Park Venture distributions; falls to 6.75% for distributions after a non-extension beyond December 31, 2028
KLX Energy Services completed its subscription rights offering on September 29, 2026, selling 24,975,001 shares at $1.49 each for $37.2 million in gross proceeds. Backstop holders of its 2030 Notes exchanged them for 59,273,445 shares, cutting outstanding principal by $94.0 million, and the company expects 105,677,168 shares outstanding afterward, so existing shareholders will be diluted. The 2030 Notes indenture was also amended to loosen leverage tests, which gives the company more covenant flexibility.
Rights offering: 24,975,001 shares sold at $1.49 per share for $37.2 million gross; $31.0 million for general corporate purposes and $6.2 million to redeem 2030 Notes at par on October 10, 2026
Backstop exchange: 59,273,445 shares issued to Backstop Parties; 2030 Notes principal reduced by $94.0 million; 105,677,168 shares expected outstanding
Indenture amended: total net leverage incurrence test relaxed from 2.50:1.00 to 3.00:1.00; maintenance covenant step-down reset to 4.50:1.00 starting with the quarter ending September 30, 2026
Levi Strauss & Co. named John Vandemore, former CFO of Skechers U.S.A., as Executive Vice President and Chief Financial Officer, effective November 1, 2026. He succeeds the role currently held by Harmit Singh, who announced his retirement in April 2026 and will serve as a Special Advisor through November 30, 2026, to support the transition.
Vandemore, 53, was CFO of Skechers U.S.A., Inc. starting November 2017 and previously held finance roles at Mattel and other firms
Base salary of $1,350,000 with an initial target bonus of 110% of base salary
Sign-on award includes a $4,000,000 cash incentive, plus RSU and SAR grants valued at $5,500,000 each
Massimo Group entered a consulting agreement with Acorn Management Partners running from September 28, 2026 to September 27, 2027, covering investor awareness, broker outreach and related services. The company will pay $15,000 per month and may issue deferred equity worth $125,000, capped at 90,000 shares, if the engagement continues past six months, which would add to shareholder dilution.
Cash compensation of $15,000 per month under the agreement dated September 28, 2026.
Deferred equity of $125,000 (capped at 90,000 shares of common stock) is due only if the engagement continues beyond the initial six-month period.
Either party may terminate for convenience on written notice, subject to the compensation provisions.
Immix Biopharma agreed on September 29, 2026 to sell 11,363,637 shares of common stock at $11.00 per share in an underwritten offering led by J.P. Morgan Securities LLC. The company expects gross proceeds of $125 million and net proceeds of approximately $117.1 million, with closing expected on September 30, 2026. The company plans to use the proceeds for NXC-201 development, working capital and general corporate purposes.
11,363,637 shares priced at $11.00 per share under an underwriting agreement with J.P. Morgan Securities LLC dated September 29, 2026
Expected gross proceeds of $125 million and net proceeds of approximately $117.1 million after underwriting discounts, commissions and offering expenses
Offering expected to close on or about September 30, 2026, subject to customary conditions; proceeds to fund NXC-201 development, working capital and general corporate purposes
Reed's entered an amendment to its senior secured loan with Whitebox-affiliated lenders and Cantor Fitzgerald as agent, converting its revolving credit commitments into $9.25 million of term loans that cannot be re-borrowed once repaid. The amendment raises the interest rate to 8.75% from 8.00%, extends maturity to June 30, 2027, and adds a new Event of Default requiring at least $10 million of cash equity contributions by November 6, 2026, which matters to shareholders because it signals tighter financing terms and a near-term capital requirement.
Revolving credit commitments converted into $9.25 million in term loans, effective September 30, 2026
Interest rate on term loans rises to 8.75% per annum from 8.00%; optional extension period accrues at 9.25%
Maturity extended to June 30, 2027, with an optional three-month extension to September 30, 2027
New Event of Default requires at least $10 million in cash equity contributions by November 6, 2026; inventory plus receivables liquidity covenant waived through that date
Inflection Point Acquisition Corp. VIII, a special purpose acquisition company, said holders of its units may separately trade Class A ordinary shares and warrants starting on or about October 5, 2026. The units, which trade under IPHXU, will continue to trade alongside the separated securities, which will trade under IPHX and IPHXW. The filing is administrative and does not change the company's search for a business combination.
Separate trading of Class A ordinary shares (IPHX) and warrants (IPHXW) begins on or about October 5, 2026
Each unit consists of one Class A ordinary share and one-third of one redeemable warrant; no fractional warrants will be issued
Initial public offering of 28,750,000 units, including 3,750,000 overallotment units, completed on August 31, 2026
Holders must have brokers contact Continental Stock Transfer & Trust Company to separate units
Grindr agreed on September 30, 2026 to acquire PurposeMed Inc., the parent company of the Freddie telehealth PrEP brand, for a base price of $250 million, consisting of $190 million in cash and $60 million in Grindr common stock. The deal also includes an earnout of up to $70 million in cash tied to PurposeMed's fiscal 2027 financial targets. Grindr said the acquisition is expected to have an immaterial impact on its 2026 financial results, and the deal is expected to close in Q4 2026, subject to closing conditions.
Base price of $250 million: $190 million in cash and $60 million in stock, or 3,851,684 shares valued at $15.58 per share
Earnout of up to $70 million in cash, tied to 2027 performance targets and payable in 2028
Freddie expects 2026 revenue of more than $80 million and Adjusted EBITDA of more than $10 million
Expected close in Q4 2026; either party may terminate if closing has not occurred by December 30, 2026
Virtuix Holdings Inc. granted its Chief Financial Officer, Thomas McGinnis, a one-time award of 100,000 restricted stock units under its 2025 Omnibus Incentive Plan. At its September 24, 2026 annual meeting, stockholders re-elected three Class I directors and ratified EisnerAmper LLP as auditor, and the board named Randolph C. Read Lead Independent Director.
Board approved 100,000 RSUs for CFO Thomas McGinnis on September 29, 2026, vesting 25% after one year and the rest in twelve quarterly installments
Stockholders elected Ugo de Charette, John Cunningham and Melissa Mohr as Class I directors, each serving until the 2029 annual meeting
Stockholders ratified EisnerAmper LLP as independent registered public accounting firm for fiscal year ending March 31, 2027, with 85,819,980 votes for
Votes represented at the meeting totaled 86,072,228, or 78.31% of voting power
TScan Therapeutics said its Chief Financial Officer, Jason A. Amello, and Chief Medical Officer, Chrystal Louis, will leave the company as part of a strategic reorganization. Both executives signed separation agreements, with employment ending on the earlier of November 1, 2026 or the date they start other paid work, and their pay and benefits continue until then.
Jason A. Amello (CFO) and Chrystal Louis, M.D., MPH (CMO) are departing under separation agreements dated September 24 and September 25, 2026.
Employment ends on the earlier of November 1, 2026 or the executive's start of other employment, consulting or paid board service.
Amello may receive a $85,000 lump-sum cash award and Louis a $125,000 award, each payable if a company milestone is achieved before their separation date under the November 2025 retention program.
Beasley Broadcast Group closed a registered direct offering and a concurrent private placement on September 30, 2026, selling 200,000 Class A shares at $14.00 each, pre-funded warrants for up to 157,000 shares, and common warrants for 357,000 shares exercisable at $15.00. The company expects net proceeds of about $4.3 million, which it plans to use with proceeds from asset sales to reduce revolver borrowings and redeem part of its 11.000% notes due 2028, but the sales add shares and warrants that could dilute existing shareholders.
200,000 Class A shares sold at $14.00 each to a single institutional investor, plus pre-funded warrants for up to 157,000 shares
Common warrants for 357,000 shares at a $15.00 exercise price, initially exercisable six months after issuance
Net proceeds of about $4.3 million after a 6.0% placement agent fee; about $2.2 million to reduce revolver borrowings and about $11.4 million to redeem 11.000% notes due 2028
Company agreed not to issue more equity for 60 days and not to enter variable rate transactions for 180 days after the September 30, 2026 closing
Exascale Labs (XLAB) appointed Jake Carney as Chief Financial Officer effective September 25, 2026, ending the interim tenure of Gildas Bonnier, whose service was no longer required after the company's formal search. The filing states Bonnier's departure was not due to any disagreement with the company over operations, policies or practices.
Jake Carney, 38, appointed CFO effective September 25, 2026
Gildas Bonnier ceased serving as Interim CFO effective September 25, 2026
Carney's base salary is $6,000 per month under his employment agreement
Filing states no disagreement led to Bonnier's departure
Bridgford Foods signed a 45-day extension of its revolving line of credit with Wells Fargo Bank, moving the maturity date to November 13, 2026, on existing terms. The filing indicates the company can borrow up to $7.5 million under the line, which is a routine financing step that keeps short-term borrowing capacity in place.
Maturity extended by 45 days to November 13, 2026, on existing terms
Credit line allows borrowing of up to $7,500,000
Interest at bank prime rate or secured overnight financing rate plus 2.0%; unused commitment fee of 0.25%
Carriage Services entered a five-year, $300 million senior secured revolving credit facility led by JPMorgan Chase, which replaces its $250 million facility, and terminated its $100 million at-the-market equity offering program effective October 4, 2026. The company says the new facility lowers borrowing costs and adds liquidity, and that it is lowering its targeted leverage range to 3.0x–3.5x. The facility is secured by a first-priority lien on substantially all company and subsidiary guarantor assets.
Revolving credit facility of up to $300 million, with an optional $100 million accordion feature that no lender is obligated to fund
Replaces the $250 million facility from May 2021; the company says the new facility expands capacity and reduces borrowing spreads
$100 million at-the-market equity program terminated effective October 4, 2026
Targeted leverage ratio lowered from 3.5x–4.0x to 3.0x–3.5x; $400 million of 4.25% Senior Notes mature in May 2029
On September 29, 2026, BioStem Technologies agreed to sell 735,296 shares at $4.08 per share, with Series A and Series B warrants, for approximately $3.0 million in gross proceeds before fees; the deal closed September 30, 2026. The filing also says a $10.0 million Clearance Payment owed to BioTissue, due by September 15, 2026, has not been made, and the company is in ongoing talks about its timing and terms. Shareholders face potential dilution from the new shares and warrants, along with an unpaid obligation.
735,296 shares at $4.08 per share, plus Series A and Series B warrants each for up to 735,296 shares at a $3.83 exercise price
Gross proceeds of approximately $3.0 million before placement agent fees; H.C. Wainwright received a cash fee of 7.0% of gross proceeds
Private placement closed September 30, 2026; resale registration statement due within 30 calendar days of the registration rights agreement
$10.0 million Clearance Payment to BioTissue was due by September 15, 2026 and had not been paid as of the filing date
Jones Lang LaSalle disclosed that Mihir Shah, CEO of Jones Lang LaSalle Technologies and a member of the Global Executive Board, will depart effective April 1, 2027. His separation agreement provides cash severance, a pro-rated incentive payment and other benefits, with equity awards treated under existing plans.
Mihir Shah leaves the company effective April 1, 2027; the separation agreement is dated September 28, 2026
Severance equals 54 weeks of base salary, or $675,000, plus a pro-rated Annual Incentive Plan payment of $590,000 and an additional payment of $2,360,000
Unvested equity awards are forfeited as of the Separation Date, with pro-rated vesting of outstanding awards based on service
Payments are conditioned on a general release of claims; the agreement includes a twelve-month non-solicitation covenant
Tevogen received written notice from Nasdaq on September 29, 2026, confirming it regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on the Nasdaq Global Market. With this and a prior September 9, 2026 notice on publicly held shares, both Nasdaq compliance matters are now closed, removing the listing deficiency concerns the company had previously disclosed.
Nasdaq notice dated September 29, 2026 confirmed compliance with the $50 million minimum market value of listed securities requirement (Rule 5450(b)(2)(A))
Earlier notice dated September 9, 2026 confirmed compliance with the minimum market value of publicly held shares requirement (Rules 5450(b)(2)(C) and 5450(b)(3)(C))
Company issued a press release on September 30, 2026, furnished as Exhibit 99.1
MSG Knickerbockers entered into agreements on September 30, 2026 to separate its New York Rangers hockey business into MSG Rangers Corp., which will be distributed to its stockholders. The company keeps sole discretion over whether to proceed, and the distribution is expected on October 26, 2026, after which shareholders will hold shares in both companies.
Record date is October 20, 2026; distribution is expected October 26, 2026.
Holders receive one MSG Rangers share for every two shares of MSG Sports common stock held at the record date.
Regular way trading of MSG Knicks (MSGK) and MSG Rangers (MSGR) is expected to begin October 27, 2026.
Completion depends on effectiveness of the Form 10, certain conditions, final league approval and a tax opinion.
Health In Tech said full-year 2026 revenue is expected to be about $33 million, roughly in line with 2025 revenue, and attributed the outlook mainly to the timing of several strategic initiatives. The company also launched HitRix, an AI-powered platform for large-group self-funded health insurance submissions, and said it expects HitRix and related initiatives to contribute more meaningfully beginning in 2027.
2026 revenue outlook of approximately $33 million, roughly in line with 2025 revenue
Outlook reflects timing of HitRix commercialization, the Three-Year Rate Stabilization Program and additional carrier capacity
HitRix platform launched September 30, 2026, for large-group self-funded health insurance workflows
Distribution ecosystem included 933 partners as of June 30, 2026, up 19.9% year over year
TTM Technologies completed its acquisition of Epiq Solutions on September 30, 2026, paying approximately $1.1 billion in cash, subject to customary adjustments. The purchase was funded with new term loans under a Third Amended and Restated Credit Agreement and proceeds from the company's 6.750% senior notes due 2034. The company expects the deal to be immediately accretive to adjusted EBITDA, moderately dilutive to non-GAAP diluted EPS in 2027, and accretive to non-GAAP diluted EPS in 2028.
Purchase price of approximately $1.1 billion in cash, paid to the seller on September 30, 2026, subject to working capital and other adjustments
New incremental facilities of $300 million term loan A and $800 million seven-year term loan B, with JPMorgan Chase Bank, N.A. as administrative agent
Company expects immediate accretion to adjusted EBITDA, moderate dilution to non-GAAP diluted EPS in 2027, and accretion in 2028
Take-Two Interactive entered a new long-term XBOX Publisher License Agreement with Microsoft, dated September 28, 2026 and effective September 17, 2026, that replaces all of its existing Xbox publisher license agreements with Microsoft. The filing describes the company's right to develop, publish, and sell Xbox-compatible products for all Xbox devices, but it does not disclose financial terms such as payment amounts or revenue share percentages.
Agreement signed September 28, 2026, with an effective date of September 17, 2026
Supersedes and replaces all of Take-Two's existing Xbox publisher license agreements with Microsoft
Microsoft has approval rights over each game concept and final version, including packaging and marketing featuring Microsoft's marks
Either party may terminate for material breach or insolvency; full text to be filed with the 10-Q for the period ending September 30, 2026
WeTouch Technology said it needs more time to complete administrative and payment processing for its previously announced special cash dividend of up to $0.5 million. The record date of August 17, 2026 and the dividend plan are unchanged, but the company has not given a new payment date. Shareholders of record may not receive the payment on the originally expected schedule until the company announces updated timing.
Special cash dividend of up to $0.5 million for shareholders of record as of August 17, 2026
Company expects additional time will be required to complete processing; no new payment date provided
Record date and dividend plan remain unchanged; updated payment timing to be announced once arrangements are finalized
No action required by eligible shareholders unless contacted by their broker, custodian, transfer agent, or other intermediary
Outlook Therapeutics received a Nasdaq notice on September 25, 2026, stating its stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, but the company has until March 24, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days.
Nasdaq notice dated September 25, 2026 cites a closing bid below $1.00 for 30 consecutive business days under Listing Rule 5550(a)(2)
Compliance Date is March 24, 2027, 180 calendar days under Rule 5810(c)(3)(A)
Company may be eligible for a second 180-day period and may need a reverse stock split; if not compliant, Nasdaq would issue a delisting notice that the company could appeal
Alamo Group said on September 29, 2026 that, as part of a review of its product portfolio, it will stop producing its Dixie Chopper branded line. The company estimates $15.0 million to $20.0 million in charges in the third quarter of 2026, including $1.0 million to $4.0 million in cash costs for inventory returns, purchase commitments and related items. The charges are estimates that depend on factors such as the net realizable value of inventory and equipment returns, and the company may record other unanticipated charges.
Company will cease production of its Dixie Chopper branded product line, decided September 29, 2026
Estimated total charges of $15.0 million to $20.0 million expected in the third quarter of 2026
Approximately $1.0 million to $4.0 million of the charges are expected to be cash expenditures
Estimates are subject to assumptions and may change; additional charges are possible
Halozyme Therapeutics elected James Daly to its Board of Directors on September 28, 2026, disclosed in a filing dated September 30, 2026. Mr. Daly was placed in the class of directors with terms ending at the 2029 annual meeting and was not initially assigned to any Board committee.
Board election date: September 28, 2026
Term ends at the company's annual meeting of stockholders in 2029
Not initially assigned to any Board committee
Compensated under the non-employee director program; no related person transactions or election arrangements disclosed
ReposiTrak reported results for the fiscal year ended June 30, 2026, with revenue up 3% to $23.3 million and GAAP net income up 8% to $7.6 million. Fourth-quarter revenue fell 3% to $5.6 million, while fourth-quarter net income rose 16% to $2.1 million. The company ended the year with $27.3 million in cash and no bank debt, and it returned $5.3 million to shareholders through dividends, buybacks and preferred redemptions.
Fiscal 2026 operating income rose 26% to $7.8 million, and operating expense fell 6% to $15.4 million.
Diluted EPS was $0.39 for fiscal 2026, compared with $0.35 a year earlier; basic EPS was $0.41.
Fourth-quarter revenue was $5.6 million, down 3% year over year; fourth-quarter diluted EPS was $0.11.
The company repurchased 143,904 common shares for $1.8 million and redeemed 175,233 preferred shares for $1.9 million during the fiscal year.
Albertsons Companies appointed three new directors, William Boltz, Chris Drumgoole and Margaret Ham, effective October 14, 2026, expanding the board from 11 to 14 members. The company also named Senior Vice President Cody Perdue as Interim Chief Financial Officer effective September 30, 2026, after Sharon McCollam's previously announced retirement, so shareholders are seeing a change in the finance leadership while a permanent CFO is sought.
Three directors appointed effective October 14, 2026: William P. Boltz, Chris Drumgoole and Margaret M. Ham; board expands from 11 to 14 directors
Cody Perdue, SVP of Treasury, Investor Relations and Risk Management, named Interim CFO effective September 30, 2026
Perdue receives a stipend at an annual rate of $350,000 during his interim service, in addition to his normal compensation
Sharon McCollam stays in an advisory role through the end of the fiscal year on February 27, 2027; the search for a permanent CFO is underway
KULR Technology Group announced on X that it has extended the pause of its at-the-market equity offering program with Cantor Fitzgerald and Craig-Hallum through December 31, 2026. The filing is a Regulation FD disclosure and reports no new financial results, but it means the company is not selling new shares through this program for a longer period.
The at-the-market equity offering program with Cantor Fitzgerald and Craig-Hallum remains paused.
The pause has been extended through December 31, 2026.
The announcement was made on September 30, 2026 through the company's X account, @kulrtech.
BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.
Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed
CTO Realty Growth entered into a $1.0 billion amended and restated unsecured credit agreement with KeyBank as administrative agent, dated September 29, 2026, replacing its prior facility. Proceeds repaid its previous $300 million revolving credit facility and two term loans of $100 million each due in January 2027 and January 2028. The company says the deal extends debt maturities to 2029 through 2032 and adds $250 million of commitments, which lengthens its weighted average debt maturity to 4.3 years from 1.6 years, excluding extension options.
Facilities total $1.0 billion: a $400 million revolver due September 2030 with two six-month extension options, plus four $150 million term loans due September 2029, September 2030, September 2031 and March 2032
Total commitments increase by $250 million, with an accordion feature allowing up to $1.5 billion in aggregate commitments
Initial fixed rates after SOFR swaps are 5.3% (2029 loan), 4.9% (2030 loan), 4.8% (2031 loan) and 3.4% (2032 loan), with the 2032 rate adjusting to about 5.3% in February 2027
Company is subject to customary restrictive covenants and financial maintenance covenants
MoonLake Immunotherapeutics said it submitted a Biologics License Application to the U.S. Food and Drug Administration on September 30, 2026, seeking approval of its tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and patients 12 years and older. The filing marks a regulatory step toward a possible approval, but the FDA has not yet decided whether to accept the application for review.
BLA submitted to the FDA on September 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativa
FDA acceptance decision expected within approximately 60 days of submission
Planned review timeline expected from the FDA within approximately 74 days of submission
Ultra Clean Holdings appointed Alexander Davern to its Board of Directors, effective September 28, 2026. The filing says he has more than 30 years of industrial technology experience, including service as CEO of National Instruments from 2017 to 2020, and the appointment does not include any financial results or guidance.
Appointed to the Board effective September 28, 2026; announced in a press release dated September 30, 2026
Previously served at National Instruments from 1994 to 2020, including as CEO from 2017 to 2020 and CFO from 1998 to 2010
Currently an independent director of Cirrus Logic, Computer Modelling Group and Spectris plc
Will receive director compensation under the non-employee director policy and is expected to sign the standard indemnification agreement
Regeneron's Compensation Committee granted CEO Leonard Schleifer and CSO George Yancopoulos one-time performance share units effective September 24, 2026, replacing their annual equity awards through 2036. Payouts depend on new product filings, approvals and revenue from new products over a performance period ending December 31, 2035, with a maximum of 2,700,000 PSUs for the CEO and 2,900,000 for the CSO. The filing also discloses that both executives received equity stakes in a newly formed, majority-owned subsidiary that the company says has nominal value and no significant assets.
Grant effective September 24, 2026; performance period runs January 1, 2026 through December 31, 2035
Revenue-based earnout starts at $10 billion of new product annual revenues and the maximum requires about $30 billion
Award caps are 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO; shares are subject to a holding period until February 2036
Both executives received stakes in a new subsidiary formed to explore a non-core business that has not yet commenced operations
Burke & Herbert Financial Services Corp. completed a $100 million public offering of 7.00% fixed-to-floating rate subordinated notes due October 1, 2036, with the offering priced at 100% of principal. The company plans to use the proceeds, plus cash on hand, to repay several existing subordinated notes and potentially redeem part of its 2021 Preferred Stock, and to provide capital to its bank subsidiary.
$100.0 million of 7.00% fixed-to-floating rate subordinated notes due October 1, 2036, sold at 100% of principal through Keefe, Bruyette & Woods, Inc.
Fixed 7.00% interest until October 1, 2031, then floating at Three-Month Term SOFR plus 222 basis points
Proceeds plus cash on hand earmarked to repay $4.5 million 2028 note, $18.1 million July 2030 notes and $20.0 million October 2030 notes, and potentially repay $75.0 million of 3.25% notes due 2031
Offering expected to close September 30, 2026; notes intended to qualify as Tier 2 capital
On September 30, 2026, Vroom Automotive, LLC, a Vroom subsidiary, issued 16,000 Series A1 and 4,000 Series B1 preferred units to SPE Holdings 2026-1 for $20 million in gross proceeds. The units carry quarterly preferential distributions tied to SOFR plus 8.50% or 9.25%, and the Series B1 units are convertible into common units of Vroom Automotive at SPE Holdings' option. Vroom Automotive expects to use the proceeds to repay certain obligations and to purchase residual interests in certain asset-backed securitization trusts.
Gross proceeds of $20,000,000 from 16,000 Series A1 and 4,000 Series B1 preferred units
Distribution rate resets quarterly at 90-day average SOFR plus 8.50% (Series A1) or 9.25% (Series B1)
Series B1 units are convertible into common units at SPE Holdings' option; Series A1 units are not convertible
Agreement and A&R LLC Agreement dated September 30, 2026, filed as exhibits 10.1 and 10.2
Bassett Furniture reported fiscal third-quarter results for the quarter ended August 29, 2026, with net sales up 3.4% to $82.8 million and operating income rising to $2.8 million from $0.6 million a year earlier. Diluted earnings per share were $0.24 versus $0.09, and the company said $1.0 million of $2.8 million in tariff refunds was recorded in gross profit this quarter, with more expected mainly in the fourth quarter. The release does not include updated full-year guidance.
Net sales were $82.8 million, up from $80.1 million; net income was $2.1 million, up from $0.8 million.
Diluted EPS was $0.24 compared with $0.09 in the prior-year quarter.
The company received $2.8 million in tariff refunds from U.S. Customs and Border Protection; $1.0 million was recorded in gross profit this quarter.
A conference call to discuss the results is scheduled for October 1, 2026, at 9:00 am ET.
ChargePoint entered a settlement term sheet on September 28, 2026 to resolve the Farooq Khan securities class action in federal court in Northern District of California. The company will pay a $11 million cash settlement, which requires Court approval, and the company denies any wrongdoing.
Cash settlement payment of $11,000,000, to be placed in escrow within 21 days after the later of preliminary Court approval or receipt of payment instructions
Company expects to sign a final Settlement Agreement and seek preliminary approval within 30 calendar days of signing the term sheet
Settlement would resolve claims against the company and former CEO Pasquale Romano, former CFO Rex Jackson, and former Chief Commercial and Revenue Officer Michael Hughes, if approved
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.